Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Dec 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how certain immune system markers can help predict how well patients with advanced melanoma will respond to a combination of two immunotherapy treatments: nivolumab and ipilimumab. These treatments work by blocking signals that keep the immune system from attacking cancer cells. The researchers want to find out if measuring levels of specific immune proteins (called cytokines) in the blood can help determine which patients will benefit from the treatment and who might experience serious side effects.

To be eligible for this study, participants must be adults with confirmed advanced melanoma who are starting their first treatment with these immunotherapies. However, those with certain types of melanoma, previous treatment with similar drugs, or active brain cancer are not eligible. If you decide to participate, you can expect to have your immune protein levels monitored before and during treatment to see how they relate to your response to therapy and any side effects you might experience. This innovative approach aims to improve treatment outcomes and enhance safety for patients with advanced melanoma.

Gender

ALL

Eligibility criteria

• • Inclusion
• • persone of major age,
• • advanced melanoma confirmed,
• • RECIST 1.1 disease,
• • first line treatment
• Exclusion Criteria:
• • occular and mucosal melanoma,
• • previous checkpoint inhibitor treatment,
• • active brain metastasis,
• • concomitant immunosuppressive treatment

Trial Officials